Analyst Price Target is $12.83
▲ +450.79% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Adicet Bio in the last 3 months. The average price target is $12.83, with a high forecast of $27.00 and a low forecast of $5.00. The average price target represents a 450.79% upside from the last price of $2.33.
Current Consensus is
Moderate Buy
The current consensus among 8 contributing investment analysts is to moderate buy stock in Adicet Bio. This Moderate Buy consensus rating has held steady for over two years.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical trial for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-270 that is in preclinical stage for the treatment of renal cell carcinoma and potential solid tumor; and ADI-002, which is undergoing preclinical studies for the treatment of hepatocellular carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
Read More